New 2026 clinical data on Caplyta and Spravato offer major new hope for the roughly 7 million Americans with treatment-resistant depression. Here’s what the evidence now shows.
Two Breakthrough Treatments Are Changing the Outlook for Americans with Treatment-Resistant Depression
by | Jun 10, 2026 | Uncategorized | 0 comments
Recent Comments